The CMT Biobank is now open! Are we coming to a city near you?

Do you want to make a difference in CMT research? HNF is looking for patients with a confirmed CMT diagnosis to participate in the CMT Biobank. Your vital blood samples and de-identified GRIN data will be shared to develop cell models of all CMT subtypes, as targets for various therapeutic approaches, and for the identification of biomarkers of CMT.

It’s easy. Simply complete the form if you are able to visit one of the following events where samples will be collected by our partner, COMBINEDBrain. There is no cost to participate.

2024 Dates:

April 4th-5th – Orlando, FL

June 7th-8th – San Diego, CA

July 20th-21st – Philadelphia, PA

July 27th-28th – Philadelphia, PA

July 27th-28th – Seattle, WA

September 27th-28th – Atlanta, GA

October 19th – Nashville, TN

December 4th-5th – Los Angeles, CA

Learn more on this topic

Related Blog Posts

Pharnext Announces PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A has Been Granted Promising Innovative Medicine (PIM) Designation by UK Medicines and Healthcare Products Regulatory Agency

United Kingdom’s Medicine and Healthcare products Regulatory Agency (MHRA) has granted Promising Innovative Medicine (PIM) designation to its lead drug candidate, PXT3003, for the treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A) in patients 16 years and older.

Pharnext raises € 7.7 million in a private placement

Pharnext SA (FR0011191287 – ALPHA) (the “Company”), a biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on its PLEOTHERAPY artificial intelligence platform harnessing big genomics data and network pharmacology, today announced a capital raise of circa € 7.7 million by way of issuance of 1,799,061 new ordinary shares (the “New Shares”) with one warrant attached each (together with the New Shares, the “ABSA”).

Join the conversation

Leave a Comment


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news